PMO Interview with the Innovator Series

How International Standards for Molecular Biomarker Testing in Lung Cancer Have Influenced Which Tests are Routinely Performed

Drs. Roy Herbst and David Rimm discuss the 50-gene panel that has become an ISLC-mandated standard for all patients with lung cancer; however, the components of cancer biomarker testing panels must be fluid and respond to new developments in the field as reported in the literature and/or at international cancer [ Read More ]

David L. Rimm, MD, PhD; Roy Herbst, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12

The Use of Next-Generation Sequencing in Treating Non-Squamous Non-Small-Cell Lung Cancer

Drs. Goeffrey Oxnard and Lauren Ritterhouse consider how next-generation sequencing (NGS) informs treatment of lung cancer patients in providing information on tumor mutational burden, microsatellite instability, unique targetable genomic signatures, as well as novel targets that may be best addressed in a clinical trial.

Geoffrey R. Oxnard, MD

Video Categories: PMO Interview with the Innovator Series: Volume 12

How PD-L1 Biomarker Test Results Impact Clinical Management of Lung Cancer

Drs. Goeffrey Oxnard and Lauren Ritterhouse review how the results of PD-L1 testing influence the choices in first- or second-line immunotherapy or combination immunochemotherapy in patients with squamous or non-squamous non-small-cell lung cancer.

Geoffrey R. Oxnard, MD; Lauren L. Ritterhouse, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12

Accurate and Reproducible Measurement of PD-1/PD-L1

Drs. Geoff Oxnard and Lauren Ritterhouse discuss PD-1/PD-L1 as a routine biomarker test run on all lung cancer biopsy specimens, as well as on other selected cancer types, and how qualitative and quantitative results are typically reported.

Geoffrey R. Oxnard, MD; Lauren L. Ritterhouse, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12

How to Foster Communication Among all Members of the Cancer Care Team with Pathologists to Deliver Individualized Treatment for Patients with Lung Cancer

Drs Roy Herbst and David Rimm consider novel ways that surgeons, interventional radiologists, pulmonologists, medical oncologists, and pathologists interact at Yale Cancer Center to maximize the use of common molecular biomarkers, as well as NGS and TMB, in providing precision medicine to lung cancer patients.

David L. Rimm, MD, PhD; Roy Herbst, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12

How the Treatment of Lung Cancer Has Been Transformed in the Era of Molecular Biomarker Testing

Drs Roy Herbst and David Rimm review how biomarker testing has transformed the way patients with lung cancer are treated, and how both medical oncologists and pathologists contribute to these changes.

David L. Rimm, MD, PhD; Roy Herbst, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12

Optimizing Communication Between Oncologists and Pathologists on Cancer Biomarker Testing

Drs Geoffrey Oxnard and Lauren Ritterhouse discuss the best ways oncologists and pathologists can communicate about molecular biomarker testing for individual patients as well as on strategies for incorporating new biomarkers into testing panels.

Geoffrey R. Oxnard, MD; Lauren L. Ritterhouse, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12

How Molecular Biomarkers Have Impacted Cancer Treatment

Drs Geoffrey Oxnard and Lauren Ritterhouse discuss the challenges and opportunities of precision medicine and molecular biomarkers in their clinical practice from an oncologist’s and a pathologist’s perspective.

Geoffrey R. Oxnard, MD; Lauren L. Ritterhouse, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12

Resistant and Mutational Cells

Dr Wainberg and Dr Gerson talk about the efficacy limitations of cytotoxic chemotherapy on some cells for a variety of reasons.

Resistant and Mutational Cells

Video Categories: Cancer Stem Cells and PMO Interview with the Innovator Series: Volume 11

Characteristics of Cancer Stem Cells

Dr Gerson offers insights into the various aspect’s of stem cells, including the ability to replicate, rest, and spread to different locations.

Characteristics of Cancer Stem Cells

Video Categories: Cancer Stem Cells and PMO Interview with the Innovator Series: Volume 11

Sign me up!